The clinical and prognostic value of CXCL8 in cervical carcinoma patients: immunohistochemical analysis

Ruiling Yan, Hanlin Shuai, Xin Luo, Xueqin Wang, Baozhang GuanBioscience 2017 · DOI

TL;DR

This study investigates the role of CXCL8, a pro-inflammatory chemokine, in cervical cancer. Researchers found that CXCL8 is significantly overexpressed in cervical cancer tissues and cell lines, and its high expression is linked to more aggressive disease and poorer patient prognosis, suggesting it could be a valuable biomarker for cervical cancer.

What Problem Does This Paper Address?

Cervical cancer remains a significant global health challenge, particularly in developing countries. While treatments like surgery, radiotherapy, and chemotherapy exist, there's a pressing need for novel biomarkers to predict clinical outcomes and identify potential therapeutic targets. The role of CXCL8, a molecule known to be involved in inflammation and increasingly implicated in various cancers as an oncogene, was poorly understood in the context of cervical cancer. This paper aims to fill that knowledge gap by examining CXCL8's expression levels and its correlation with clinical characteristics and prognosis in cervical cancer patients.

Methods

The researchers employed a multi-pronged approach to investigate CXCL8:

  • Microarray Analysis: They analyzed publicly available gene expression datasets (GSE9750 and GSE7803) to compare CXCL8 mRNA levels in cervical cancer tissues versus normal cervical tissues and cervical intraepithelial lesions.
  • Quantitative Real-Time PCR (qRT-PCR): This technique was used to measure CXCL8 mRNA expression in both cervical cancer tissues and cell lines compared to their normal counterparts.
  • Western Blot: This method was utilized to assess CXCL8 protein expression levels in cervical cancer tissues and cell lines.
  • Immunohistochemistry (IHC): This was the primary method for evaluating CXCL8 protein expression in a cohort of 108 cervical cancer tissue samples and 25 normal cervical tissue samples. IHC also allowed for the correlation of CXCL8 expression with various clinicopathological features.
  • Statistical Analysis: A range of statistical tests were employed, including Wilcoxon signed-rank test, Student's t-test, chi-square test, Kaplan-Meier survival analysis, and Cox regression (univariate and multivariate) to analyze the data and determine the significance of findings.
  • Database Analysis: The Cancer Genome Atlas (TCGA) database was used to analyze the prognostic significance of CXCL8 in a larger cohort of cervical cancer patients.

Datasets

  • Microarray Datasets:
    • GSE9750: Included normal cervical tissues and cervical cancer tissues.
  • GSE7803: Included normal cervical tissues, cervical intraepithelial lesions tissues, and cervical cancer tissues.
  • Clinical Samples: 108 cervical cancer tissue samples and 25 normal cervical tissue samples collected from the First Affiliated Hospital of Jinan University.
  • Cell Lines: Human cervical squamous cell carcinoma cell line (Caski), human cervical adenocarcinoma cell line (HeLa), human normal ectocervical cell line (Ect1/E6E7), and human normal endocervical cell line (End1/E6E7).
  • The Cancer Genome Atlas (TCGA) Database: Used to analyze the prognostic significance of CXCL8 in a cohort of 246 cervical squamous cell carcinoma and endocervical adenocarcinoma patients.

Key Insights and Ideas

  • CXCL8 as an Oncogene in Cervical Cancer: The study strongly suggests that CXCL8 isn't just a marker of inflammation but actively contributes to the oncogenic process in cervical cancer, mirroring its role in other cancer types.
  • CXCL8 as a Prognostic Indicator: The most significant finding is that high CXCL8 expression is a poor independent prognostic parameter. This means patients with higher CXCL8 levels are more likely to have worse outcomes, making it a potential tool for risk stratification.
  • Multifaceted Overexpression: CXCL8 isn't just overexpressed at the mRNA level; its protein expression is also significantly elevated in cancer tissues and cell lines, indicating a robust biological effect.
  • Correlation with Malignancy: The strong association between CXCL8 expression and clinical stage, distant metastasis, histological type, and grade highlights its link to more aggressive and advanced disease.

Key Results

  • High Expression in Cancer: CXCL8 mRNA and protein were significantly overexpressed in cervical cancer tissues and cell lines compared to normal counterparts. Microarray data showed higher CXCL8 expression in cancer tissues (GSE9750, GSE7803). qRT-PCR confirmed higher mRNA levels in cancer tissues (P<0.001). Western blot also indicated elevated protein levels.
  • Immunohistochemistry Findings: In the cohort of 108 cervical cancer patients, 56.5% showed high CXCL8 protein expression, compared to only 29.6% in normal cervical tissues (P=0.013).
  • Correlation with Clinicopathological Features: CXCL8 protein expression was significantly correlated with:
  • Clinical stage (P=0.009)

    • Distant metastasis (P=0.045)
    • Histological type (adenocarcinoma vs. squamous cell carcinoma, P<0.001)
    • Histological grade (well vs. moderately/poorly, P<0.001) It was not correlated with age, tumor size, or lymph node metastasis.
  • Prognostic Significance:

    • Kaplan-Meier survival analysis in the study cohort showed that patients with high CXCL8 expression had significantly shorter overall survival (P<0.001).
  • Analysis of the TCGA database (246 patients) also revealed that high CXCL8 expression was associated with shorter overall survival (P<0.001).
  • Univariate and multivariate Cox regression analyses identified high CXCL8 expression as an unfavorable independent prognostic factor (multivariate P=0.030).

Limitations and Future Work

  • Sample Size: The authors acknowledge that the limited sample size of patients in their study necessitates further research to verify these findings and establish CXCL8's role as a reliable clinical predictor.
  • Heterogeneity: The authors briefly mention that discrepancies in other studies might be due to the heterogeneity of human cancers, implying that cervical cancer might also have subtypes with varying CXCL8 roles.
  • Mechanism of Action: While the paper establishes the correlation and prognostic value, it doesn't delve deeply into the precise molecular mechanisms by which CXCL8 drives cervical cancer progression. Future work could explore how CXCL8 signaling pathways influence tumor growth, invasion, and metastasis in cervical cancer.
  • Therapeutic Potential: The study highlights the potential for CXCL8 signaling pathway inhibitors as therapeutic agents for cervical cancer, given the observed overexpression. Further preclinical and clinical studies are warranted to explore this avenue.

Summary updated

Abstract

Cysteine-X-cysteine ligand 8 (CXCL8) was originally discovered as a proinflammatory chemokine. Recently, CXCL8 has been shown to act as an oncogene in several types of human cancers. However, the clinical and prognostic significance of CXCL8 in cervical cancer is poorly understood. In our study, we found that CXCL8 was highly expressed in cervical cancer tissues compared with normal cervical tissues in microarray datasets (GSE9750 and GSE7803). <i>CXCL8</i> mRNA and protein expressions were increased in cervical cancer tissues and cell lines compared with normal cervical tissues and cervical epithelial cell lines. CXCL8 protein expression was significantly correlated with clinical stage, distant metastasis, histological type, and histological grade. CXCL8 high expression was a poor independent prognostic parameter for cervical cancer patients. In conclusion, CXCL8 is highly expressed in cervical cancer tissues and cell lines, and correlated with malignant status and prognosis in cervical cancer patients.
BibTeX
@inproceedings{yan2017clinical,
  author = {Ruiling Yan and Hanlin Shuai and Xin Luo and Xueqin Wang and Baozhang Guan},
  title = {{The clinical and prognostic value of CXCL8 in cervical carcinoma patients: immunohistochemical analysis}},
  booktitle = {Bioscience},
  year = {2017},
  doi = {10.1042/bsr20171021},
}
Figure